circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
amplicon Any DNA or RNA sequence or fragment that is the source and/or product of an amplification reaction. The term is most frequently used to describe the numerous copied fragments that are the products of the polymerase chain reaction or ligase chain reaction, though it may also refer to sequences that are amplified naturally within a genome, e.g. by gene duplication.
Sanger then turned to sequencing DNA, which would require an entirely different approach. He looked at different ways of using DNA polymerase I from E. coli to copy single-stranded DNA. In 1975, together with Alan Coulson, he published a sequencing procedure using DNA polymerase with radiolabelled nucleotides that he called the "Plus and Minus" technique. This involved two closely related methods that generated short oligonucleotides with defined 3' termini. These could be fractionated by electrophoresis on a polyacrylamide gel and visualised using autoradiography. The procedure could sequence up to 80 nucleotides in one go and was a big improvement on what had gone before, but was still very laborious. Nevertheless, his group were able to sequence most of the 5,386 nucleotides of the single-stranded bacteriophage φX174. This was the first fully sequenced DNA-based genome. To their surprise they discovered that the coding regions of some of the genes overlapped with one another. In 1977 Sanger and colleagues introduced the "dideoxy" chain-termination method for sequencing DNA molecules, also known as the "Sanger method". This was a major breakthrough and allowed long stretches of DNA to be rapidly and accurately sequenced. It earned him his second Nobel prize in Chemistry in 1980, which he shared with Walter Gilbert and Paul Berg. The new method was used by Sanger and colleagues to sequence human mitochondrial DNA (16,569 base pairs) and bacteriophage λ (48,502 base pairs). The dideoxy method was eventually used to sequence the entire human genome.
While no other government actively supported the Boer cause, individuals from several countries volunteered and formed Foreign Volunteer Units. These primarily came from Europe, particularly the Netherlands, Germany and Sweden-Norway. Other countries such as France, Italy, Ireland (then part of the United Kingdom), and restive areas of the Russian Empire, including Congress Poland and Georgia, also formed smaller volunteer corps. Finns fought in the Scandinavian Corps. Two volunteers, George Henri Anne-Marie Victor de Villebois-Mareuil of France and Yevgeny Maximov of Russia, became veggeneraals (fighting generals) of the South African Republic.
Sources: en.wikipedia.org
French Armed Forces Minister Sébastien Lecornu announced that France would donate dozens of armoured vehicles to the Lebanese military to help it carry out patrol missions. Since June 2024, the foreign ministries of Canada, Kuwait, Germany, the Netherlands and North Macedonia issued statements urging their citizens to leave Lebanon due to fears of an escalation of the conflict. The Canadian Armed Forces said that it was planning to evacuate its 20,000 citizens from Lebanon in the event of an escalation, although it would require support from its allies. On 8 November 2023, two men were arrested by Brazilian police in São Paulo following a warning from Mossad that Hezbollah was planning an attack against the country's Jewish community. Searches were also conducted in Brasília and Minas Gerais in connection with the alleged plot.
Sweden and Finland are furthest along in committing to a particular disposal technology, while many others reprocess spent fuel or contract with France or Great Britain to do it, taking back the resulting plutonium and high-level waste. "An increasing backlog of plutonium from reprocessing is developing in many countries... It is doubtful that reprocessing makes economic sense in the present environment of cheap uranium." In many European countries (e.g., Britain, Finland, the Netherlands, Sweden, and Switzerland) the risk or dose limit for a member of the public exposed to radiation from a future high-level nuclear waste facility is considerably more stringent than that suggested by the International Commission on Radiation Protection or proposed in the United States. European limits are often more stringent than the standard suggested in 1990 by the International Commission on Radiation Protection by a factor of 20, and more stringent by a factor of ten than the standard proposed by the U.S. Environmental Protection Agency (EPA) for the Yucca Mountain nuclear waste repository for the first 10,000 years after closure. The U.S. EPA's proposed standard for greater than 10,000 years is 250 times more permissive than the European limit. The U.S.
=== NPH insulin === NPH insulin, also known as isophane insulin, is an intermediate-acting insulin used to manage blood sugar levels in individuals with diabetes. The name NPH is an abbreviation for "neutral protamine Hagedorn", referring to neutral pH (pH = 7), protamine a protein attached to the insulin molecule, and Hans Christian Hagedorn, the insulin researcher who developed this formulation. It was designed to enhance insulin delivery and is one of the early examples of engineered drug delivery. It is typically administered through subcutaneous injection once or twice daily. Its effects usually begin within an hour and last for 24 hours. There are versions available that are premixed with short-acting insulins, such as regular insulin. The most common side effect is low blood sugar (hypoglycemia). Other potential side effects may include pain or skin changes at the injection sites, low blood potassium, and allergic reactions. It is generally considered safe for use during pregnancy for the fetus. NPH insulin is produced by mixing regular insulin and protamine in precise proportions with zinc and phenol to maintain a neutral pH and form crystals. There are versions based on human and pig insulin. Protamine insulin was first created in 1936, and NPH insulin was introduced in 1946. It is included in the World Health Organization's List of Essential Medicines In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.
== Amino acid metabolism == When more sulfur containing amino acids, methionine and cystine, are consumed than the body can use for growth and repair, they are broken down yielding sulfate, or sulfuric acid among other products. Animal foods such as meat, dairy, and eggs are high in protein and "dietary animal protein intake is highly correlated with renal net acid excretion". Research dating back to the early 1900s has shown correlations between high protein diets and increased acid excretion. One measure of the acidic or basic effects foods have in the body is Potential Renal Acid Load (PRAL). Cheeses with protein content of 15 g protein/100g or higher have a high PRAL value of 23.6 mEq/100 g edible portion. Meats, fish, other cheeses and flour or noodles all have a PRAL around 8.0 mEq/100 g edible portion, where fruits and vegetables actually have a negative PRAL. In healthy adults, bone undergoes constant repair and renewal. New bone is deposited by osteoblast cells and resorbed or destroyed by osteoclast cells. This addition and subtraction of bone usually yields no net change in the overall mass of the skeleton, but the turnover process can be significantly affected by pH.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.